Attached files

file filename
EX-99.1 - EX-99.1 - Axogen, Inc.axgn-20190115ex99168eb80.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 15, 2019

 

AXOGEN, INC.

(Exact name of registrant as specified in its charter)

 

Minnesota

    

001-36046

    

41-1301878

(State or other jurisdiction of

 

(Commission File Number)

 

(IRS Employer Identification No.)

incorporation)

 

 

 

 

 

13631 Progress Boulevard, Suite 400,

    

 

Alachua, Florida

 

32615

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code

 

(386) 462-6800

(Former name or former address if changed since last report,)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 


 

Item 8.01 Other Events

 

On January 15, 2019, AxoGen, Inc. (the “Company”) issued a press release announcing information regarding the Company’s RECON® study which supports its Biologic License Application Submission for Avance® Nerve  Graft. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.

 

Item 9.01. Financial Statements and Exhibits

 

(d)     Exhibits

 

P

 

 

Exhibit No.

    

Description

99.1

 

AxoGen, Inc. Press Release, dated January 15, 2019.

 


 

EXHIBIT INDEX

 

 

 

 

Exhibit No.

    

Description

99.1

 

AxoGen, Inc. Press Release, dated January 15, 2019.

 


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

AXOGEN, INC.

 

 

Date: January 15, 2019

By:

/s/ Gregory G. Freitag

 

 

Gregory G. Freitag

 

 

General Counsel